News|Articles|September 6, 2023

Novartis Hires Patrick Horber as President, International

Appointment comes amid resignation of Marie-France Tschudin from company executive committee.

Effective Sept. 15, Marie-France Tschudin, president, innovative medicines international, chief commercial officer, will be leaving Novartis. In her place, the company has added Patrick Horber with the title of president, international. Currently, Horber works as SVP and president, immunology, AbbVie.

A native of Switzerland with an MD from the University of Zurich, Horber will join Novartis with over 20 years of experience in the biopharma field.

"As a Swiss medical doctor, it is a privilege to join Novartis—a pillar of global biomedical innovation and scientific progress,” said Horber, in a company press release. “I look forward to working alongside our teams to reimagine medicine for and with patients around the globe.”

Reference: Novartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of Novartis. Novartis. September 6, 2023. Accessed September 6, 2023. https://www.novartis.com/news/media-releases/novartis-appoints-patrick-horber-md-president-international-marie-france-tschudin-president-innovative-medicines-international-and-chief-commercial-officer-steps-down-from-executive-committee-novartis


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.